title: HIV-Host Interactions: Implications for Vaccine Design.
abstract: Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV type 1 (HIV-1), which is a consequence of its propensity to mutate to escape immune responses, along with host factors that prevent the elicitation of protective immune responses, continue to hinder vaccine development. Breakthroughs in understanding of the biology of the transmitted virus, the structure and nature of its envelope trimer, vaccine-induced CD8 T cell control in primates, and host control of broadly neutralizing antibody elicitation have given rise to new vaccine strategies. Despite this promise, emerging data from preclinical trials reinforce the need for additional insight into virus-host biology in order to facilitate the development of a successful vaccine.
authors.affiliation: Department of Medicine, Duke University, Durham, NC 27710, USA; Department of Immunology, Duke University, Durham, NC 27710, USA; Duke University Human Vaccine Institute, Duke University, Durham, NC 27710, USA. Electronic address: barton.haynes@duke.edu.
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
authors.affiliation: Departments of Medicine and Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
authors.forename: George M
authors.initials: GM
authors.lastname: Shaw
authors.affiliation: Los Alamos National Laboratory, Los Alamos, NM 87544, USA.
authors.forename: Bette
authors.initials: B
authors.lastname: Korber
authors.affiliation: Department of Immunology, Duke University, Durham, NC 27710, USA; Duke University Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
authors.forename: Garnett
authors.initials: G
authors.lastname: Kelsoe
authors.affiliation: Dana Farber-Cancer Institute, Harvard Medical School, Harvard University, Boston, MA 02215, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Sodroski
authors.affiliation: Departments of Medicine and Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
authors.forename: Beatrice H
authors.initials: BH
authors.lastname: Hahn
authors.affiliation: Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
authors.forename: Persephone
authors.initials: P
authors.lastname: Borrow
authors.affiliation: Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: McMichael
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000302:isolation & purification; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D055808:Drug Discovery / Q000379:methods / Q000639:trends; D004353:Drug Evaluation, Preclinical; D015483:HIV Antibodies / Q000276:immunology; D015497:HIV-1 / Q000276:immunology* / Q000472:pathogenicity*; D054884:Host-Pathogen Interactions; D011323:Primates; D016896:Treatment Outcome
chemical_list: D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies